FDA-cleared profile

aPROMISE

EXINI Diagnostics AB · PET/SPECT/Nuclear Medicine · FDA-cleared (510(k))

Authorized purpose: aPROMISE is a cloud-based platform for healthcare professionals and researchers to accept, transfer, store, display, manipulate, quantify, and report PSMA PET/CT examinations using the PROMISE framework.

Clinical role
PET/CT visualization, segmentation, quantification, quality control, and structured reporting support.
Images and patients
PET/SPECT/Nuclear Medicine · Prostate
Key limitation
Keep in mind: Both aPROMISE and the predicate aBSI rely on the user to make the final selection of regions of interest that are considered as lesions. To create a report the signing user is required to confirm quality control, and electronically sign the report preview.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: aPROMISE is a cloud-based platform for healthcare professionals and researchers to accept, transfer, store, display, manipulate, quantify, and report PSMA PET/CT examinations using the PROMISE framework.
  • Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Prostate Input: PSMA PET/CT image data in the form of DICOM files.
  • Who uses it?Intended users: Healthcare professionals and researchers.
  • What does the software produce?Output: The review page displays studies in a 4-panel view showing PET, CT, PET/CT fusion and maximum intensity projection (MIP) simultaneously. Selected or drawn hotspots are subject to automatic quantitative analysis. Signed reports are saved in the device and can be exported as a JPG or DICOM file.
  • What is its most important limitation?Key limitation: Both aPROMISE and the predicate aBSI rely on the user to make the final selection of regions of interest that are considered as lesions. To create a report the signing user is required to confirm quality control, and electronically sign the report preview.

Clinical takeaway. Clinical role: aPROMISE is a cloud-based platform for healthcare professionals and researchers to accept, transfer, store, display, manipulate, quantify, and report PSMA PET/CT examinations using the PROMISE framework.

Evidence takeaway. Evidence from the reviewed source record: K211655 reports phantom validation, predicate comparison, analytical performance, and a clinical study comparing platform-supported PSMA PET/CT quantification with clinician assessment. The FDA summary does not provide one universal sensitivity or specificity value; exact tracer, acquisition, and version applicability must be checked before using candidate publications as performance evidence.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
aPROMISE is a cloud-based platform for healthcare professionals and researchers to accept, transfer, store, display, manipulate, quantify, and report PSMA PET/CT examinations using the PROMISE framework.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
PET/CT visualization, segmentation, quantification, quality control, and structured reporting support.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
PSMA PET/CT image data in the form of DICOM files.
  • Exact FDA submission
  • Checked 2026-09-19

The direct packet input statement replaces the current radiopharmaceutical-metadata addition.

Output and clinician action
The review page displays studies in a 4-panel view showing PET, CT, PET/CT fusion and maximum intensity projection (MIP) simultaneously. Selected or drawn hotspots are subject to automatic quantitative analysis. Signed reports are saved in the device and can be exported as a JPG or DICOM file.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet supports PET/CT visualization, hotspot analysis, quantitative analysis, and signed-report export; it does not state the current disease-burden wording.

Care setting
Molecular-imaging departments or validated research workflows using supported DICOM PET/CT examinations.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Healthcare professionals and researchers.
  • Exact FDA submission
  • Checked 2026-09-19

This is the exact intended-user class in the indication statement; the current qualified-specialist role list is not stated.

Limitations
Both aPROMISE and the predicate aBSI rely on the user to make the final selection of regions of interest that are considered as lesions. To create a report the signing user is required to confirm quality control, and electronically sign the report preview.
  • Exact FDA submission
  • Checked 2026-09-19

These are the packet's direct user-confirmation and report-quality-control boundaries; tracer, acquisition, reconstruction, and literature limitations are not stated in this packet.

Evidence summary
K211655 reports phantom validation, predicate comparison, analytical performance, and a clinical study comparing platform-supported PSMA PET/CT quantification with clinician assessment. The FDA summary does not provide one universal sensitivity or specificity value; exact tracer, acquisition, and version applicability must be checked before using candidate publications as performance evidence.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K211655 reports phantom validation, predicate comparison, analytical performance, and a clinical study comparing platform-supported PSMA PET/CT quantification with clinician assessment. The FDA summary does not provide one universal sensitivity or specificity value; exact tracer, acquisition, and version applicability must be checked before using candidate publications as performance evidence.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K211655 FDA performance package for aPROMISE

  • DesignManufacturer phantom, analytical, predicate-comparison, and clinical performance validation
  • PopulationPSMA PET/CT examinations for prostate-cancer imaging, quantification, and structured reporting
  • Scopeexact submission
  • Tested versionaPROMISE
  • IndependenceSponsor or vendor study

K211655

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

4 unlinked candidate evidence records are retained for source review and excluded from this evidence display.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K211655 by exact submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: PSMA PET/CT image data in the form of DICOM files.

    Scope: Exact FDA submission. The direct packet input statement replaces the current radiopharmaceutical-metadata addition.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K211655: aPROMISE

  2. Routing

    Source context, not route validation: K211655 describes DICOM transfer, a four-panel PET/CT/fusion/MIP display, ROI quantification, user quality control, electronic report confirmation, and archival workflow. Current EXINI or PYlarify material is product-family context and does not prove the exact deployed cloud configuration.

    Scope: Product family. Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K211655: aPROMISE · EXINI aPROMISE product-family context

  3. AI processing

    Source context, not route validation: Cloud-based web platform as described in K211655; confirm hosting region, tenant isolation, identity, retention, and current product build with the vendor.

    Scope: Product family. Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K211655: aPROMISE · EXINI aPROMISE product-family context

  4. Returned objects

    Source context, not route validation: The review page displays studies in a 4-panel view showing PET, CT, PET/CT fusion and maximum intensity projection (MIP) simultaneously. Selected or drawn hotspots are subject to automatic quantitative analysis. Signed reports are saved in the device and can be exported as a JPG or DICOM file.

    Scope: Exact FDA submission. The exact packet supports PET/CT visualization, hotspot analysis, quantitative analysis, and signed-report export; it does not state the current disease-burden wording.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K211655: aPROMISE

  5. Viewer/worklist/report

    Unresolved route: The review page displays studies in a 4-panel view showing PET, CT, PET/CT fusion and maximum intensity projection (MIP) simultaneously. Selected or drawn hotspots are subject to automatic quantitative analysis. Signed reports are saved in the device and can be exported as a JPG or DICOM file.

    Scope: Exact FDA submission. The exact packet supports PET/CT visualization, hotspot analysis, quantitative analysis, and signed-report export; it does not state the current disease-burden wording.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K211655: aPROMISE

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Cloud-based web platform as described in K211655; confirm hosting region, tenant isolation, identity, retention, and current product build with the vendor.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Integration
K211655 describes DICOM transfer, a four-panel PET/CT/fusion/MIP display, ROI quantification, user quality control, electronic report confirmation, and archival workflow. Current EXINI or PYlarify material is product-family context and does not prove the exact deployed cloud configuration.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Security
EXINI Diagnostics AB publishes a coordinated vulnerability disclosure policy covering EXINI products: vulnerability intake at support@exini.com, safe harbor for good-faith security researchers, coordinated disclosure timing, and investigation and patch handling commitments.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The policy covers EXINI products generally and does not name aPROMISE or any specific release; exact-release scope is not established.

Training
Only qualified nuclear medicine physicians, radiologists, and trained imaging analysts should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Quantification depends on tracer, acquisition, reconstruction, segmentation, image quality, and user quality-control steps; candidate literature and current family materials do not establish exact-version performance unless explicitly linked to the submission.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K211655 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

K211655 describes DICOM transfer, a four-panel PET/CT/fusion/MIP display, ROI quantification, user quality control, electronic report confirmation, and archival workflow. Current EXINI or PYlarify material is product-family context and does not prove the exact deployed cloud configuration.

product family · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Quantification depends on tracer, acquisition, reconstruction, segmentation, image quality, and user quality-control steps; candidate literature and current family materials do not establish exact-version performance unless explicitly linked to the submission.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Quantification depends on tracer, acquisition, reconstruction, segmentation, image quality, and user quality-control steps; candidate literature and current family materials do not establish exact-version performance unless explicitly linked to the submission.

product family · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K211655
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
PET/SPECT/Nuclear Medicine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The packet identifies NM imaging using PSMA PET/CT and does not establish the current SPECT expansion. Controlled directory display reconciled from exact FDA wording: Nuclear medicine (NM) imaging using PSMA PET/CT. -> PET/SPECT/Nuclear Medicine.

Anatomy
Prostate
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The packet directly refers to body scans; it does not state prostate anatomy in the reviewed indication or summary. Controlled directory display reconciled from exact FDA wording: Body scans of PSMA PET/CT image data. -> Prostate.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-07-27
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
14Source classes checked
9Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 9 PubMed and 1 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 9 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

18 sources - 3 history items

Source ledger

  1. FDA K211655: aPROMISE

    U.S. Food and Drug Administration - Published 2021-07-27 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. EXINI aPROMISE product-family context

    EXINI Diagnostics - Accessed 2026-09-03

    Scope: productFamilyContext, integration, deployment

  8. PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  9. Comparison of diagnostic performance between manual diagnosis following PROMISE V2 and aPROMISE utilizing Ga/F-PSMA PET/CT.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  10. Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  11. Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  12. aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL Images of Veterans with Prostate Cancer.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  13. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [(18)F]DCFPyL (PSMA) imaging for standardized reporting.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  14. Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  15. Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  16. Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  17. Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  18. EXINI Diagnostics AB: Coordinated Vulnerability Disclosure Policy

    EXINI Diagnostics AB - Accessed 2026-10-27

    Scope: security

Research history

  1. K211655 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K221680

Xeleris V Processing and Review System

GE Healthcare

Authorized purpose: The Xeleris V Processing and Review System displays, processes, archives, prints, reports, and networks planar, SPECT, and PET nuclear-medicine data, with optional applications for DaTQUANT, lung analysis, brain analysis, coronary-flow reserve, prostate-cancer bone metastases, liver shunt and dose calculations, and monitoring of patient radiation doses from nuclear-medicine imaging data.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, lung, brain, liver, cardiac, coronary, and other anatomy represented in labeled nuclear-medicine studies
Decision
2023-03-01
FDA-cleared K251528

syngo.via MI Workflows; Scenium; syngo MBF

Siemens Medical Solutions USA, Inc.

Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-07-03
FDA-cleared K251153

Aurora

GE Medical Systems Israel

Authorized purpose: Aurora is a SPECT/CT system for nuclear-medicine uptake imaging, standalone CT, anatomical localization, attenuation correction, diagnosis, staging, therapy planning, guidance, and monitoring. K251153 adds deep-learning kidney segmentation to dynamic renal scintigraphy.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-06-12
FDA-cleared K243863

Opulus™ Lymphoma Precision

Roche Molecular Systems, Inc.

Authorized purpose: Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole-body FDG-PET/CT
Decision
2025-05-30

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history